Renal clear cell carcinoma targeting peptide aiming at carbonic anhydrase IX, targeting probe and application thereof

By designing the combination of carbonic anhydrase IX targeting peptide and infrared fluorescent dye, the problem of insufficient targeting in renal clear cell carcinoma surgery was solved, and the precise positioning and precise resection of the tumor was achieved, reducing the risk of surgical trauma and recurrence.

CN118978569APending Publication Date: 2024-11-19ZHONGDA HOSPITAL SOUTHEAST UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411057905.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-02
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art cannot accurately target tumors in renal clear cell carcinoma surgery, resulting in high difficulty in surgery, high trauma, high risk of recurrence, and lack of specific small molecule aptamers.

Method used

Design and synthesize carbonic anhydrase IX targeted polypeptide, coupled to infrared fluorescent dyes, used for optical imaging-assisted surgical navigation, to achieve accurate tumor positioning and precise resection.

Benefits of technology

The specific targeting of renal clear cell carcinoma is achieved, reducing the risk of surgical trauma and recurrence, and improving the early recovery rate of renal function.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118978569A_ABST
    Figure CN118978569A_ABST
Patent Text Reader

Abstract

The invention discloses a renal clear cell carcinoma targeting peptide aiming at carbonic anhydrase IX, a targeting probe and application thereof, and belongs to the field of biomedical engineering. A series of novel targeting peptides aiming at the carbonic anhydrase IX are designed and synthesized, and the targeting peptides can be specifically combined with renal clear cell tumor by targeting the carbonic anhydrase IX and can be used for optical imaging and surgical navigation of renal cancer tumors. The high-affinity polypeptide coupled infrared fluorescent dye can be used as a tumor specific targeting molecular probe, can accurately position tumor boundaries, can bring real-time performance for preoperative and intraoperative image navigation, and has the advantage of improving operation accuracy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedical engineering, and in particular to a renal clear cell carcinoma targeting peptide and a targeting probe for carbonic anhydrase IX and applications thereof. Background Art

[0002] Renal cell carcinoma (RCC) is a common tumor of the urinary system, accounting for 5% of male tumors and 3% of female tumors, of which clear cell carcinoma accounts for the vast majority. With the change of detection mode, the incidence of renal cancer is still showing a gradual increase. Most renal tumors are discovered during physical examinations. About 60% of newly diagnosed renal tumors are stage I renal cancer. The clinical prognosis of early renal cancer after surgical treatment is generally good, but about 25% of stage I renal cancer patients will still metastasize. Partial nephrectomy is used to treat early renal cancer, which preserves more kidney tissue, avoids renal function impairment, and ensures the treatment effect of the tumor.

[0003] A variety of auxiliary methods have been tried for intraoperative tumor localization and margin judgment, among which fluorescence imaging technology has a certain guiding role in showing tumor blood flow blockage and tumor range. After the tumor supply artery branch is blocked during surgery, indocyanine green (ICG) is used intravenously, and the renal blood perfusion can be displayed in real time through the da Vinci si robot fluorescence imaging lens. However, ICG is non-tumor-targeted and cannot accurately display the exact location and contour of the tumor, especially for the surgical treatment of completely endogenous tumors or complex renal tumors. The practical application significance is limited. In addition, the operation requires complete free exposure of the renal branch artery, which is difficult, has a long learning curve, and has many related complications, which is not conducive to widespread implementation. Therefore, the clinical application value of ICG fluorescence imaging technology is limited.

[0004] In order to make up for the lack of ICG's non-tumor targeting, some studies have used ICG to couple small molecules or monoclonal antibodies and short peptides to achieve targeted binding to tumors for robot-assisted laparoscopic prostate cancer surgery. However, renal clear cell carcinoma lacks such specific small molecule aptamers. How to target tumors, accurately remove lesions, and preserve renal units as much as possible during robot-assisted laparoscopic partial nephrectomy, thereby ensuring early recovery of renal function after renal tumor surgery, is still a dilemma.

[0005] Carbonic anhydrase IX (CAIX) is expressed in 95% of renal clear cell carcinomas. It is a renal clear cell specific tumor-associated antigen and an ideal target binding protein. The humanized chimeric monoclonal antibody Girentuximab can specifically recognize CAIX. Clinical studies have shown that the antibody has excellent sensitivity and specificity, which is higher than traditional 18F-PET / CT. However, due to the large size, poor in vivo pharmacokinetics and poor immunogenicity of monoclonal antibodies, their clinical application is limited. Compared with antibodies, peptides usually have a relatively short circulation half-life, low immunogenicity and good immunoactive permeability, and are easy to chemically modify, so they are more suitable for clinical imaging examinations. Therefore, obtaining a carbonic anhydrase IX targeting peptide is particularly important for solving the problems existing in the existing technology. Summary of the invention

[0006] The purpose of the present invention is to provide a renal clear cell carcinoma targeting peptide, targeting probe and application thereof for carbonic anhydrase IX, so as to solve the problems existing in the above-mentioned prior art. A new type of carbonic anhydrase IX targeting polypeptide is designed and synthesized. This type of polypeptide can specifically target renal clear cell carcinoma tumors. The coupling of infrared fluorescent dyes can perform optical imaging to assist doctors in accurately locating tumor boundaries during surgery when using molecular imaging surgical navigation equipment, so as to achieve the purpose of accurate tumor resection, thereby reducing trauma to patients and reducing the risk of postoperative recurrence.

[0007] To achieve the above object, the present invention provides the following solutions:

[0008] The present invention provides a renal clear cell carcinoma targeting peptide, wherein the amino acid sequence of the targeting peptide is any one of the sequences shown in SEQ ID NOs: 1-3:

[0009] SEQ ID NO: 1 is: Ser-Ser-Asn-Met-Arg-Pro-Glu-Leu-Ser-Ser-Met-Arg-NH2;

[0010] SEQ ID NO: 2 is: Leu-Ser-Thr-Ala-Phe-Ala-Arg-Val-Asp-Glu-NH2;

[0011] SEQ ID NO: 3 is: Leu-Arg-Asn-Asn-Gly-His-Ser-Val-Gln-Leu-NH2.

[0012] The present invention also provides a renal clear cell carcinoma targeting probe, the chemical structure of which is shown below:

[0013]

[0014] Wherein, R is the targeting peptide according to claim 1, and L is a linker.

[0015] Preferably, the structural formula of the linking agent is any one of the following L1-L6:

[0016]

[0017] The present invention also provides a method for preparing the renal clear cell carcinoma targeting probe, comprising the following steps:

[0018] The solid-phase synthesized targeting peptide is mixed with a linker for reaction to obtain an intermediate product;

[0019] After the intermediate product and the dye MPA are dissolved, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and N,N-diisopropylethylamine are added to react, and after the reaction is completed, separation and purification are performed to obtain the renal clear cell carcinoma targeting probe.

[0020] Preferably, the mass ratio of the targeting peptide to the linker is 10:(6-7), and the mixing reaction is carried out at 35° C. for 5-8 hours.

[0021] Preferably, the reagent for dissolving the targeting peptide and the linker is dimethyl sulfoxide, and the ratio of the targeting peptide, the linker and dimethyl sulfoxide is (5-12) mg: (10-15) mg: 500 μL;

[0022] The mass ratio of the targeting peptide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and N,N-diisopropylethylamine is (5-12):(2-5):(3-5):(4-6);

[0023] The reaction conditions are: reaction at room temperature for 8-12 hours.

[0024] The present invention also provides a drug for diagnosing, treating or tracing renal clear cell carcinoma, comprising the targeting peptide or the targeting probe.

[0025] The present invention also provides the use of the targeting peptide or the targeting probe in preparing drugs for diagnosing, treating and tracing renal clear cell carcinoma.

[0026] The present invention also provides the use of the targeting peptide or the targeting probe in preparing targeted gene therapy and chemotherapy drugs for renal clear cell carcinoma.

[0027] Preferably, the targeted gene is the renal clear cell carcinoma carbonic anhydrase IX gene.

[0028] The present invention discloses the following technical effects:

[0029] (1) The ZDHC-X series polypeptides discovered in the present invention are low molecular weight polypeptides with low synthesis cost. The in vivo and in vitro experimental results show that this series of probes have excellent targeting properties in vivo and in vitro.

[0030] (2) In vivo optical imaging of the ZDHC-X series of peptides has shown that they have excellent imaging effects on renal clear cell tumors. Their ability to specifically target tumor sites will make it possible to diagnose malignant tumors and use optical imaging to guide surgeons in surgical navigation, thereby achieving precise resection of lesions.

[0031] (3) The present invention uses near-infrared fluorescent dye MPA, which has more ideal stability and water solubility, as an optical imaging group, thereby improving the pharmacokinetics of the drug in vivo.

[0032] (4) The present invention introduces linker chains (L) with different properties to further improve the pharmacokinetic properties, especially the clearance kinetics from non-tumor tissues. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0034] Figure 1 The chemical structure (A), HPLC analysis chart (B) and MS chart (C) of the peptide ZDHC-1;

[0035] Figure 2 The chemical structure (A), HPLC analysis (B) and MS (C) of the fluorescent targeting probe MPA-L1-ZDHC-1;

[0036] Figure 3 Flow cytometry experiments for the targeted probe MPA-L1-ZDHC-X;

[0037] Figure 4 This is the optical imaging image of the probe MPA-L1-ZDHC-1 in renal clear cell tumor CAKI-2 bearing mice;

[0038] Figure 5 This is the optical imaging of MPA-L1-ZDHC-1 in renal clear cell tumor CAKI-2 bearing mice after being blocked by peptide ZDHC-1;

[0039] Figure 6 This is the optical imaging image of the probe MPA-L2-ZDHC-1 in the renal clear cell tumor OS-RC-2 bearing mouse;

[0040] Figure 7 This is the optical imaging image of the probe MPA-L5-ZDHC-2 in renal clear cell tumor OS-RC-2 bearing mice;

[0041] Figure 8 This is the optical imaging image of the probe MPA-L6-ZDHC-2 in renal clear cell tumor CAKI-2 bearing mice;

[0042] Fig. 9 This is the optical imaging image of the probe MPA-L3-ZDHC-3 in renal clear cell tumor CAKI-2 bearing mice;

[0043] Fig.10 This is a surgical navigation diagram for the probe MPA-L4-ZDHC-1 in mice bearing renal clear cell tumor OS-RC-2. DETAILED DESCRIPTION

[0044] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0045] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.

[0046] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.

[0047] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.

[0048] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.

[0049] Example 1 Synthesis of polypeptide ZDHC-1

[0050] 1) Resin swelling

[0051] Weigh RinkAmide MBHA resin, put it into the reaction column, add an appropriate amount of dichloromethane (DCM), and gently blow nitrogen for 10-30 minutes to allow the resin to fully swell. Drain the DCM solution, wash it with dimethylformamide (DMF) three times, and drain it.

[0052] 2) Removal of fluorenylmethoxycarbonyl (Fmoc)

[0053] A 20% DMF solution of piperidine was added to the reaction column, and the column was deprotected once every 5 minutes and once every 8 minutes. After the reaction was completed, the column was washed with DMF for 6 times.

[0054] 3) Coupling

[0055] Accurately weigh 3 times the molar number of the feed resin Fmoc-Arg-OH and O-benzotriazole-N,N,N',N'-tetramethyluronium tetrafluoroborate (TBTU), completely dissolve in DMF, add N,N-diisopropylethylamine (DIPEA) to activate the carboxyl group, and then add the solution to the reaction column for reaction. After 1 hour, the detection structure is positive. Remove Fmoc from the C-terminus to the N-terminus in sequence until the last amino acid Fmoc-Ser-OH is coupled. After removing Fmoc, shrink the target resin peptide and weigh it.

[0056] 4) Lysis

[0057] Prepare 87.5% TFA + 5% thioanisole + 2.5% ethanedithiol + 2.5% phenol + 2.5% water lysis solution, slowly add the lysis solution to the resin peptide under low temperature conditions, the volume of the cutting solution is 7-8 times the weight of the crude peptide resin, slowly stir for 2 hours, filter the liquid, add ice ether and stir, then centrifuge to obtain a solid, wash three times with ether, drain and weigh, and measure the mass-to-charge ratio to determine the molecular weight.

[0058] 5) Purification and separation

[0059] The purification was performed by high performance liquid chromatography, the chromatographic filler for purification was 10 μm reverse phase C18, the mobile phase system was 0.1% TFA / water solution and 0.1% TFA / acetonitrile solution, the gradient system was used for elution, and the cyclic injection purification was performed. The crude product solution was loaded on the chromatographic column, the mobile phase elution was started, the main peak was collected and the acetonitrile was evaporated to obtain the target peptide concentrate, and then the target polypeptide was obtained by freeze-drying. The obtained product was confirmed to be the expected product ZDHC-1 by analytical HPLC and ESI-MS mass spectrometry analysis. The chemical structure, HPLC analysis chart and MS chart are shown in Figure 1 .

[0060] Product ZDHC-2 and product ZDHC-3 were synthesized in the same manner.

[0061] The sequence of ZDHC-X (X=1-3) is as follows:

[0062] ZDHC-1:Ser-Ser-Asn-Met-Arg-Pro-Glu-Leu-Ser-Ser-Met-Arg-NH2;

[0063] ZDHC-2:Leu-Ser-Thr-Ala-Phe-Ala-Arg-Val-Asp-Glu-NH2;

[0064] ZDHC-3:Leu-Arg-Asn-Asn-Gly-His-Ser-Val-Gln-Leu-NH2.

[0065] Example 2 Preparation of fluorescent targeting probe MPA-L1-ZDHC-1

[0066] Weigh 10 mg of the solid-phase synthesized ZDHC-1 polypeptide, dissolve it in 1 mL of dichloromethane (DCM), add condensing agent 2-(7-azabenzotriazole)-N,N,N',N'-tetramethyluronium hexafluorophosphate (HATU) 5.06 mg, Boc-L1-OH (connector peptide) 6.88 mg and 6.2 mg N,N-diisopropylethylamine (DIPEA), shake well and react at 35 ° C for 6 hours, monitor the reaction by high performance liquid chromatography, after the reaction is completed, spin dry the solvent, add 400 μL of trifluoroacetic acid, react at room temperature for another 2 hours, then spin dry the trifluoroacetic acid, and dissolve the crude product in 800 μL of an equal proportion of acetonitrile and water. Use preparative liquid phase for separation and purification to obtain compound L1-ZDHC-1, which is lyophilized for use.

[0067] Weigh 10 mg of the above-synthesized compound L1-ZDHC-1 and 12.38 mg of pure fluorescent dye MPA and add them to 500 μL of dimethyl sulfoxide (DMSO), then add 2.3 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI) condensation agent and 3.82 mg of N-hydroxysuccinimide (NHS), mix well, and then add 4.1 mg of N, N-diisopropylethylamine (DIPEA), react at room temperature overnight, and after the reaction is completed, use preparative liquid phase for separation and purification. The preparative liquid phase conditions are as follows:

[0068] Agilent 1260 Infinity II series HPLC system equipped with Agilent ZORBAX SB-C18 semi-preparative column (9.4×250 mm, 5 μm) was used, gradient elution was 40 minutes, flow rate was 2 mL / min, mobile phase A was ultrapure water (0.01% TFA), B was acetonitrile (0.01% TFA). The elution gradient was set as: 90% A and 10% B at 0-10 minutes, 75% A and 25% B at 25 minutes, and 50% A and 50% B at 40 minutes. The green product finally obtained was confirmed to be the expected product MPA-L1-ZDHC-1 by analytical HPLC and ESI-MS mass spectrometry analysis. The chemical structure, HPLC analysis chart and MS chart are shown in Figure 2 .

[0069] In the above preparation process, the L1-ZDHC-1 polypeptide used in the step is replaced by the L-ZDHC-X polypeptide to obtain various other polypeptide compounds having tumor-targeting optical imaging function of the present invention.

[0070] The structure of the linker L is shown below:

[0071]

[0072] Example 3 Flow cytometry experiment of targeted probe MPA-L1-ZDHC-X

[0073] The specific steps are as follows:

[0074] 1) First, prepare a 12-well plate, digest the cells that are in good growth condition and free of bacteria, count them using the counting plate counting method, add the same amount of cells to each well of the 12-well plate, and then place it in a cell culture incubator at 37°C and 5% CO2 for 24 hours.

[0075] 2) After the cells have grown for 24 hours, the culture medium in the 12-well plate was discarded, and 500 μL of fresh culture medium without serum was added. Different groups were set up: blank group Control, single dye group MPA, and experimental group. MPA and peptide probe were added respectively to a final concentration of 5 μM in the well plate, and then continued to be cultured in the incubator for 3 hours.

[0076] 3) Sample treatment before flow cytometry: discard the old culture medium in the well plate, digest with 0.05% trypsin, add culture medium containing 10% fetal bovine serum to resuspend, transfer the cell suspension to a 1.5 mL EP tube, centrifuge at 1000 rpm for 5 min, wash three times with 500 μL PBS buffer (pH 7.2), and finally add 500 μL PBS buffer (pH 7.2) to resuspend for later use.

[0077] 4) Determination of cell fluorescence intensity by flow cytometry: Set the flow cytometer parameters, the flow rate is medium flow rate, and the cell injection is 50,000 cells. Load the sample and measure the fluorescence intensity of each group, and the fluorescence intensity relative to the control group and the single dye group.

[0078] 5) Data processing: FlowJo 7.0 software was used to generate peak graphs of the raw data and calculate the mean fluorescence intensity (MFI). GraphPad Prism software was used to quantitatively plot the mean fluorescence intensity and perform data difference analysis. The results are shown in Figure 3 .

[0079] Example 4 Optical imaging of the targeted probe MPA-L1-ZDHC-1 in renal clear cell tumor CAKI-2 bearing mice

[0080] The targeted probe MPA-L1-ZDHC-1 prepared in Example 2 was prepared into a physiological saline solution, and 0.1 mL (about 10 nmol) was injected into the tail vein of three renal clear cell tumor CAKI-2 nude mice (weight about 22 g), and optical signal collection was performed 1, 2, 4, 8, 12, and 24 hours after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0081] The imaging results are as follows Figure 4 As shown in the figure, the imaging results of the probe MPA-L1-ZDHC-1 in the three tumor-bearing nude mice are basically consistent. From the 2-hour imaging image, it can be seen that the probe has been obviously taken up in the tumor, and the probe is still retained in the tumor until 24 hours. Among them, the probe is most enriched in the tumor site at 4 hours, while the uptake and clearance in other background organs is faster. From the signal of the bladder, it can be inferred that this probe is mainly metabolized by the kidneys.

[0082] Example 5 Optical imaging of MPA-L1-ZDHC-1 in renal clear cell tumor CAKI-2 bearing mice after peptide ZDHC-1 blocking

[0083] 500 μg of unlabeled peptide ZDHC-1 was dissolved in 0.1 mL of saline and injected into three nude mice bearing renal clear cell tumor CAKI-2. 5 minutes later, 0.1 mL of saline solution of probe MPA-L1-ZDHC-1 (10 nmol) was injected. Optical signal acquisition was performed at 1, 2, 4, 8, 12, and 24 hours after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0084] The imaging results are as follows Figure 5As shown, the imaging results of the fluorescent probe MPA-L1-ZDHC-1 in three tumor-bearing nude mice are basically consistent. It can be clearly seen from the optical images at each time point that after being blocked in advance with the unlabeled fluorescent dye polypeptide ZDHC-1, no obvious fluorescent signal was observed at the tumor site, which indicates that the binding of the probe MPA-L1-ZDHC-1 to the tumor site in vivo is specific.

[0085] Example 6 Optical imaging of probe MPA-L2-ZDHC-1 in renal clear cell tumor OS-RC-2 bearing mice

[0086] Compound MPA-L2-ZDHC-1 was prepared in the same manner as in Example 2 and prepared into a physiological saline solution. 0.1 mL (about 10 nmol) was injected into the tail vein of three renal clear cell tumor OS-RC-2 nude mice (weight about 23 g), and optical signal collection was performed at 0, 1, 2, 4, 8, and 12 h after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0087] The imaging results are as follows Figure 6 As shown, the probe MPA-L2-ZDHC-1 was significantly taken up in the tumor site, indicating that this probe could target renal clear cell tumor OS-RC-2 tumor cells and be mainly metabolized and excreted from the body through the kidneys.

[0088] Example 7 Optical Imaging of Probe MPA-L5-ZDHC-2 in Renal Clear Cell Tumor OS-RC-2 Tumor-Bearing Mice

[0089] The probe MPA-L5-ZDHC-2 was prepared in the same manner as in Example 2 and prepared into a physiological saline solution. 0.1 mL (about 10 nmol) was injected into the tail vein of three renal clear cell tumor OS-RC-2 nude mice (weight about 23 g), and optical signal collection was performed 1, 2, 4, 8, 12, and 24 h after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0090] 4h imaging results Figure 7 As shown, the probe MPA-L5-ZDHC-2 was significantly taken up in the tumor site, indicating that this probe could target renal clear cell tumor OS-RC-2 cells and be mainly metabolized and excreted from the body through the kidneys.

[0091] Example 8 Optical Imaging of Probe MPA-L6-ZDHC-2 in Renal Clear Cell Tumor CAKI-2 Tumor-Bearing Mice

[0092] The probe MPA-L6-ZDHC-2 was prepared according to the method of Example 2 and prepared into a physiological saline solution. 0.1 mL (about 10 nmol) was injected into the tail vein of three renal clear cell tumor CAKI-2 nude mice, and optical signals were collected 1, 2, 4, 8, 12, and 24 hours after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0093] 4h imaging results Figure 8 As shown, the probe MPA-L6-ZDHC-2 was significantly taken up in the tumor site, indicating that this probe could target renal clear cell tumor CAKI-2 cells and was mainly metabolized and excreted from the body through the kidneys.

[0094] Example 9 Optical Imaging of Probe MPA-L3-ZDHC-3 in Renal Clear Cell Tumor CAKI-2 Tumor-Bearing Mice

[0095] The probe MPA-L3-ZDHC-3 was prepared according to the method of Example 2 and prepared into a physiological saline solution. 0.1 mL (about 10 nmol) was injected into the tail vein of three renal clear cell tumor CAKI-2 nude mice, and optical signals were collected 1, 2, 4, 8, 12, and 24 hours after administration. The distribution of the probe in the mouse body and its enrichment in the tumor area were observed.

[0096] 4h imaging results Fig. 9 As shown, the probe MPA-L3-ZDHC-3 was significantly taken up in the tumor site, indicating that this probe can target renal clear cell tumor CAKI-2 cells and is mainly metabolized and excreted from the body through the kidneys.

[0097] Example 10 Probe MPA-L4-ZDHC-1 for surgical navigation in OS-RC-2 renal clear cell tumor-bearing mice

[0098] The optimal time point for surgical navigation was determined by imaging effect diagrams. After the MPA-L4-ZDHC-1 probe was injected into the tail vein, 4% chloral hydrate was injected intraperitoneally into the mice. The mice were placed under a near-infrared imaging system and partial resections were performed on orthotopic tumor models and metastatic tumor models. These procedures were used to simulate the resection of tumor positive margins and invasive and metastatic lesions ( Fig.10 ). Tissues with fluorescent hot spots were removed, and positive suspicious tumors and other marginally negative sampling tissues were collected for sectioning and staining, and other tissues of the same type without focal fluorescent signals were taken for pathological analysis.

[0099] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.

Claims

1. A renal clear cell carcinoma targeting peptide, characterized in that: The amino acid sequence of the targeting peptide is any one of the sequences shown in SEQ ID NOs: 1-3.

2. A renal clear cell carcinoma targeting probe, characterized in that: Its chemical structure is shown below: Wherein, R is the targeting peptide according to claim 1, and L is a linker.

3. The renal clear cell carcinoma targeting probe according to claim 2, characterized in that The structural formula of the linking agent is any one of the following L1-L6:

4. A method for preparing a renal clear cell carcinoma targeting probe according to claim 2 or 3, characterized in that: The following steps are involved: The solid-phase synthesized targeting peptide is mixed with a linker for reaction to obtain an intermediate product; After the intermediate product and the dye MPA are dissolved, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and N,N-diisopropylethylamine are added to react, and after the reaction is completed, separation and purification are performed to obtain the renal clear cell carcinoma targeting probe.

5. The preparation method according to claim 4, characterized in that: The mass ratio of the targeting peptide to the linker is 10:(6-7), and the mixed reaction is carried out at 35° C. for 5-8 hours.

6. The preparation method according to claim 4, characterized in that: The reagent for dissolving the targeting peptide and the linker is dimethyl sulfoxide, and the ratio of the targeting peptide, the linker and dimethyl sulfoxide is (5-12) mg: (10-15) mg: 500 μL; The mass ratio of the targeting peptide, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride, N-hydroxysuccinimide and N,N-diisopropylethylamine is (5-12):(2-5):(3-5):(4-6); The reaction conditions are: reaction at room temperature for 8-12 hours.

7. A drug for diagnosing, treating or tracing renal clear cell carcinoma, characterized in that: It comprises the targeting peptide according to claim 1 or the targeting probe according to claim 2.

8. Use of the targeting peptide according to claim 1 or the targeting probe according to claim 2 in the preparation of drugs for diagnosis, treatment and tracing of renal clear cell carcinoma.

9. Use of the targeting peptide according to claim 1 or the targeting probe according to claim 2 in the preparation of drugs for targeted gene therapy and chemotherapy of renal clear cell carcinoma.

10. The use according to claim 9, characterized in that The targeted gene is the carbonic anhydrase IX gene targeting renal clear cell carcinoma.